A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Parabilis Medicines, Inc.
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
Eisai Inc.
Terremoto Biosciences Inc.
GlaxoSmithKline
Artios Pharma Ltd
PMV Pharmaceuticals, Inc
Mayo Clinic
Qilu Pharmaceutical Co., Ltd.
Children's Oncology Group
AstraZeneca
Arvinas Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
DualityBio Inc.
Beijing Tide Pharmaceutical Co., Ltd
Second Life Therapeutics
Tanabe Pharma America, Inc.
GV20 Therapeutics
Laekna Limited
Alaunos Therapeutics
Eli Lilly and Company
LigaChem Biosciences, Inc.
Bolt Biotherapeutics, Inc.
Incyte Corporation
Incyte Corporation
Cancer Research UK
NuCana plc
Hutchmed
PharmaMar
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Esperas Pharma Inc.
Portage Biotech
Aminex Therapeutics, Inc.
NextCure, Inc.
Mundipharma Research Limited
NextCure, Inc.
ImmVira Pharma Co. Ltd
Western Sydney Local Health District
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Incyte Corporation
Incyte Corporation
Incyte Corporation
Seagen Inc.
Gilead Sciences
Novartis